A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine-Reference-Cited by-同舟云学术

A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine

Published:2022-04-15 Issue:7 Volume:37 Page:1416-1424
ISSN:0885-3185
Container-title:Movement Disorders
language:en
Short-container-title:Movement Disorders

Author:

Yu Hui Jing¹^ORCID,Thijssen Eva²³^ORCID,van Brummelen Emilie²,van der Plas Johan L.²³,Radanovic Igor²,Moerland Matthijs²,Hsieh Eric¹,Groeneveld Geert Jan²³,Dodart Jean‐Cosme¹

Affiliation:

1. Vaxxinity Inc. Dallas Texas USA

2. Centre for Human Drug Research Leiden the Netherlands

3. Leiden University Medical Centre Leiden the Netherlands

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mds.29016

Reference31 articles.

1. Current and projected future economic burden of Parkinson’s disease in the U.S.

2. Parkinson disease

3. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

4. Potential Modes of Intercellular α-Synuclein Transmission

5. How the shapes of seeds can influence pathology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial;Nature Medicine;2024-06-20

2. An update on multiple system atrophy;Current Opinion in Neurology;2024-06-03

3. Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond;Current Neuropharmacology;2024-05

4. Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work?;Parkinsonism & Related Disorders;2024-05

5. Nonintuitive Immunogenicity and Plasticity of Alpha-Synuclein Conformers: A Paradigm for Smart Delivery of Neuro-Immunotherapeutics;Pharmaceutics;2024-04-30